XPG is a DNA endonuclease that is essential for the dual incision step of nucleotide excision repair (cleaves 3′ of the DNA lesion). XPG might be involved in the DNA replication and repair deficiency syndromes Cockayne Syndrome and Xeroderma pigmentosa.
| Inventor | Institute |
|---|---|
| Susheela Dhut | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| Cat. #: | 151063 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Genetics |
| Application: | IF ; ELISA ; FACS ; IHC ; IF ; IP ; WB |
| Target: | XPG |
| Reactivity: | Human |
| Clone: | 8H7/XPG |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | XPG is a DNA endonuclease that is essential for the dual incision step of nucleotide excision repair (cleaves 3' of the DNA lesion). XPG might be involved in the DNA replication and repair deficiency syndromes Cockayne Syndrome and Xeroderma pigmentosa. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG2a |
| Molecular weight: | 185 kDa |
| Immunogen: | Recombinant human XPG protein produced in baculovirus |
| Immunogen Uniprot ID: | Q62199 |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | XPG is a DNA endonuclease that is essential for the dual incision step of nucleotide excision repair (cleaves 3' of the DNA lesion). XPG might be involved in the DNA replication and repair deficiency syndromes Cockayne Syndrome and Xeroderma pigmentosa. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
HCMV-infected cells maintain efficient nucleotide excision repair of the viral genome while abrogating repair of the host genome. O'Dowd et al. 2012. PLoS Pathog. 8(11):e1003038. PMID: 23209410. Igoucheva et al. 2006. Oligonucleotides. 16(1):94-104. PMID: 16584298. Bomgarden et al. 2006. EMBO J. 25(11):2605-14. PMID: 16675950. Opposing effects of the UV lesion repair protein XPA and UV bypass polymerase eta on ATR checkpoint signaling. Involvement of ERCC1/XPF and XPG in oligodeoxynucleotide-directed gene modification. Arajo et al. 2001. Mol Cell Biol. 21(7):2281-91. PMID: 11259578. Strong Fn interactions of TFIIH with XPC and XPG in human DNA nucleotide excision repair, without a preassembled repairosome. Evans et al. 1997. EMBO J. 16(3):625-38. PMID: 9034344. Open complex formation around a lesion during nucleotide excision repair provides a structure for cleavage by human XPG protein. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151022 | Anti-IL12 [1-1A4] |
Key Info
Anti-IL12 [1-1A4]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.